Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre recombinase/LoxP system for prostate cancer cells under androgen ablation condition

Japanese Journal of Cancer Research

Volumn 93, Issue 10, 2002, Pages 1154-1163

  Ikegami, Shusei ^a   Tadakuma, Takushi ^a   Suzuki, Satoshi ^a   Yoshimura, Ichiro ^a   Asano, Tomohiko ^a   Hayakawa, Masamichi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Androgen; Cre loxP system; Gene therapy; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

CARBOXYPEPTIDASE; CRE RECOMBINASE; GANCICLOVIR; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; INTEGRASE; MEMBRANE ANTIGEN; THYMIDINE KINASE; VIRUS PROTEIN; ANDROGEN; LUCIFERASE; PLASMID DNA; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; ENHANCER REGION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METHODOLOGY; MOUSE; NUDE MOUSE; PROMOTER REGION; PROSTATE TUMOR; XENOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CONTROLLED STUDY; DNA RECOMBINATION; HERPES SIMPLEX VIRUS; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; SUICIDE GENE THERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; ENHANCER ELEMENTS (GENETICS); GANCICLOVIR; GENE THERAPY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INTEGRASES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; THYMIDINE KINASE; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VIRAL PROTEINS;

EID: 0036808742     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb01218.x     Document Type: Article

References (43)

1. Gotoh, A., Ko, S. C., Shirakawa, T., Cheon, J., Kao, C., Miyamoto, T., Gardner, T. A., Ho, L. J., Cleutjens, C. B. J., Trapman, J., Graham, F. L. and Chung, L. W. K. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J. Urol., 160, 220-229 (1998).
2. Latham, J. P. F., Searle, P. F., Mautner, V. and James, N. D. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res., 60, 334-341 (2000).
3. Pang, S., Dannull, J., Kaboo, R., Xie, Y., Tso, C. L., Michel, K., Dekernion, J. B. and Belldegrun, A. S. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res., 57, 495-499 (1997).
4. Suzuki, S., Tadakuma, T., Asano T. and Hayakawa, M. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations. Cancer Res., 61, 1276-1279 (2001).
5. Israeli, R. S., Powell, C. T., Fair, W. R. and Heston, W. D. W. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res., 53, 227-230 (1993).
6. Bostwick, D. G., Pacelli, A., Blute, M., Roche, P. and Murphy, G. P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer, 82, 2256-2261 (1998).
7. Israeli, R. S., Powell, C. T., Corr, J. G., Fair, W. R. and Heston, W. D. W. Expression of the prostate-specific membrane antigen. Cancer Res., 54, 1807-1811 (1994).
8. Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. W. and Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res., 3, 81-85 (1997).
9. Wright, G. L., Jr., Harley, C., Beckett, M. L. and Schellhammer, P. F. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol. Oncol., 1, 18-28 (1995).
10. Chang, S. S., O'Keef, D. S., Bacich, D. J., Reutter, V. E., Heston, W. D. W. and Gaudin, P. B. Prostate-specific membrane antigen is produced in tumor-associated neovasculture. Clin. Cancer Res., 5, 2674-2681 (1999).
11. Kawasaki, M. and Nakayama, J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res., 57, 2321-2324 (1997).
12. Wright, G. L., Jr., Grob, B. M., Harley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F. and Moriatry, R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 48, 326-334 (1996).
13. Sternberg, N. and Hamilton, D. Bacteriophage P1 site-specific recombination I. Recombination between loxP sites. J. Mol. Biol., 150, 467-486 (1981).
14. Sato, Y., Tanaka, K., Lee, G., Kanegae, Y., Sakai, Y., Kaneko, S., Nakabayashi, H., Tamaoki, T. and Saito, I. Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. Biochem. Biophys. Res. Commun., 224, 455-462 (1998).
15. Suzuki, S., Tadakuma, T., Kunitomi, T., Takayama, E., Sato, M., Asano, T., Nakamura, H. and Hayakawa, M. Liposome-mediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells. Urol. Int., 67, 216-223 (2001).
16. O'Keef, D. S., Su, S. L., Bacich, D. J., Horiguchi, Y., Luo, Y., Powell, C. T., Zandvliet, D., Russell, P. J., Molloy, P. L., Nowak, N. J., Shows, T. B., Mullins, C., Vonder Haar, R. A., Fair, W. R. and Heston, W. D. W. Mapping, genomic organization and promoter analysis of human prostate-specific membrane antigen gene. Biochem. Biophys. Acta, 1443, 113-117 (1998).
17. O'Keef, D. S., Uchida, A., Bacich, D. J., Watt, F. B., Martorana, A., Molly, P. L. and Heston, W. D. W. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate, 45, 149-157 (2000).
18. Logan, J. J., Bebok, Z., Walker, L. C., Peng, S., Felgner, P. L., Siegel, G. P., Frizell, R. A., Dong, J., Howard, M., Matalon, S., Lindsey, J. R., Du Vail, M. and Sorscher, E. J. Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium. Gene Ther., 2, 38-49 (1995).
19. Kunitomi, M., Takayama, E., Suzuki, S., Yasuda, T., Tsutsui, K., Nagaike, K., Hiroi, S. and Tadakuma, T. Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human α-fetoprotein gene. Jpn. J. Cancer Res., 91, 343-350 (2000).
20. Sugaya, S., Fujita, K., Kikuchi, A., Ueda, H., Takakuwa, K., Kodama, S. and Tanaka, K. Inhibition of tumor growth by direct intratumoral gene transfer of herpes simplex virus thymidine kinase gene with DNA-liposome complexes. Hum. Gene Ther., 7, 223-230 (1996).
21. Zou, Y., Peng, H., Zhou, B., Wen, Y., Wang, S. C., Tsai, E. M. and Hung, M. C. Systemic tumor suppression by pro-apoptotic gene bik. Cancer Res., 62, 8-12 (2002).
22. Gleave, M., Hsieh, J. T., Gao, C., Von Eschenbach, A. C. and Chung, L. W. K. Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 51, 3753-3761 (1991).
23. Good, D., Schwarzenberger, P., Eastham, J. A., Rhoads, R. E., Hunt, J. D., Collins, M., Batzer, M., Theodossiou, C., Kolls, J. K. and Grimes, S. R. Cloning and characterization of the prostate-specific membrane antigen promoter. J. Cell. Biochem., 74, 395-405 (1999).
24. Uchida, A., O'Keef, D. S., Bacich, D. J., Molloy, P. L. and Heston, W. D. W. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology, 58, 132-139 (2001).
25. Gao, M., Ossowski, L. and Ferrari, A. C. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J. Cell. Physiol., 179, 336-346 (1999).
26. Hall, S. J., Mutchnik, S. E., Yang, G., Timme, T. L., Nasu, Y., Bangma, C. H., Woo, S. L., Shaker, M. and Thompson, T. C. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther., 6, 54-63 (1999).
27. Marcelli, M., Cunningham, G. R., Walkup, M., He, Z., Sturgis, L., Kagan, C., Mannucci, R., Nicoletti, I., Teng, B. and Denner, L. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res., 59, 382-390 (1999).
28. Lockett, L. J., Molloy, P. L., Russell, P. J. and Both, G. W. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin. Cancer Res., 3, 2075-2080 (1997).
29. Brand, K., Loser, P., Arnold, W., Bartels, T. and Strauss, M. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSV/GCV approach. Gene Ther., 5, 1363-1371 (1998).
30. Ichikawa, T., Tamiya, T., Adachi, Y., Ono, Y., Matsumoto, K., Furuta, T., Yoshida, Y., Hamada, H. and Ohtomo, T. In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther., 7, 73-82 (2000).
31. Maron, A., Havaux, N., Roux, A., Knoops, B., Perricaudet, M. and Octave, J. N. Differential toxicity of ganciclovir for rat neurons and astrocytes in primary culture following adenovirus-mediated transfer of the HSV-tk gene. Gene Ther., 4, 25-31 (1997).
32. Lehrman, S. Virus treatment questioned after gene therapy death. Nature, 401, 517-518 (1999).
33. Hamel, W., Magnelli, L., Chiarugi, V. P. and Israel, M. A. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res., 56, 2697-2702 (1996).
34. Mesnil, M., Piccoh, C., Tiraby, G., Willecke, K. and Yamasaki, H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA, 93, 1831-1835 (1996).
35. Nomura, T., Nakajima, S., Kawabata, K., Yamashita, F., Takakura, Y. and Hashida, M. Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res., 57, 2681-2686 (1997).
36. Huber, B. E., Austin, E. A., Richards, C. A. and Davis, S. T. Metabolism of 5-fluorocytosine to 5-fluouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA, 91, 8302-8306 (1994).
37. Takakuwa, K., Fujita, K., Kikuchi, A., Sugaya, S., Yahata, T., Aida, H., Kurabayashi, T., Hasegawa, I. and Tanaka, K. Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissue. Jpn. J. Cancer Res., 88, 166-175 (1997).
38. Chang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S. and Gaudine, P. B. Five different antiprostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res., 59, 3192-3198 (1999).
39. Grauer, L. S., Lawler, K. D., Marignac, J. L., Kumar, A., Goel, A. S. and Wolfert, R. L. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res., 58, 4787-4789 (1998).
40. Murphy, G. P., Greene, T. G., Tino, W. T., Boynton, A. L. and Holmes, E. H. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J. Urol., 160, 2396-2401 (1998).
41. Smith-Jones, P. M., Vallabahajosula, S., Goldsmith, S. J., Navarro, V., Hunter, C. J., Bastidas, D. and Bander, N. H. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res., 60, 5237-5243 (2000).
42. 213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res., 61, 2008-2014 (2001).
43. 213J591) for radioimmunotherapy of prostate cancer. Cancer Res., 60, 6095-6100 (2000).